Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ifetroban SCHEMBL28135 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Ifetroban SCHEMBL30218601 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL28137 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL28136 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL9589119 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| SCHEMBL8918573 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| SCHEMBL8918962 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL16212977 | 0.99 | TBXA2R (0.98) | TBXA2R | |
| Bms-180291 SCHEMBL362595 | 0.99 | TBXA2R (0.98) | TBXA2R | |
| Ifetroban SCHEMBL16212975 | 0.99 | TBXA2R (0.98) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114334-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2025-04-10 | — | — | US | claimed |
| US-20250049764-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | CUMBERLAND PHARMACEUTICALS INC. | 2025-02-13 | — | — | US | claimed |
| US-20230381147-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2023-11-30 | — | — | US | claimed |
| US-20230270726-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | VANDERBILT UNIVERSITY | 2023-08-31 | — | — | US | claimed |
| EP-3454850-B1 | COMPOSITIONS AND METHODS OF TREATING MUSCULAR DYSTROPHY WITH THROMBOXANE-A2 RECEPTOR ANTAGONISTS | CUMBERLAND PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | claimed |
| US-20220133696-A1 | Ifetroban Treatment for Systemic Sclerosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-05 | — | — | US | claimed |
| US-20250114334-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20250049764-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | CUMBERLAND PHARMACEUTICALS INC. | 2025-02-13 | — | — | US | disclosed |
| US-12161632-B2 | Compositions and methods of treating cardiac fibrosis with ifetroban | CUMBERLAND PHARMACEUTICALS INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230381147-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2023-11-30 | — | — | US | disclosed |
| US-20230270726-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | VANDERBILT UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| EP-3454850-B1 | COMPOSITIONS AND METHODS OF TREATING MUSCULAR DYSTROPHY WITH THROMBOXANE-A2 RECEPTOR ANTAGONISTS | CUMBERLAND PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230129262-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 | OGLETREE MARTIN (US) | 2023-04-27 | — | — | US | disclosed |
| US-11571412-B2 | Thromboxane receptor antagonists in AERD/asthma | CUMBERLAND PHARMACEUTICALS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-115666560-A | Methods and pharmaceutical compositions for treating thromboxane A2 receptor antagonists of COVID-19 | 马丁·奥格特树 | 2023-01-31 | — | — | CN | disclosed |
| US-20220218672-A1 | Thromboxane Receptor Antagonists in AERD/Asthma | CUMBERLAND PHARMACEUTICALS INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220133696-A1 | Ifetroban Treatment for Systemic Sclerosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-05 | — | — | US | disclosed |